Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Response Biomedical (V.RBM) -- Ignore unavailable to you. Want to Upgrade?

To: Dick Martin who wrote (588)	3/16/2006 8:54:56 PM
From: Starowl	Read Replies (1) \| Respond to of 655

Dick, Strong relationship between ID Biomedical's interests and RBM's, as indicated in this news release from 15 months ago. ID Biomedical was/is working on an avian flu vaccine with RBM working on a system to detect the strain: "Canada's pandemic flu vaccine maker is finalizing negotiations to import the seed strain needed to make a vaccine against the devastating H5N1 avian influenza virus, company officials have revealed. "ID Biomedical hopes to have the hybrid virus in the country before the holidays to begin work that could ultimately trim precious time off the vaccine production schedule when a flu pandemic is declared, company executives told The Canadian Press. "It's all about shaving down time," chief executive officer Dr. Tony Holler said in an interview in Quebec City, where ID Biomedical's production plant is located. "The company will begin growing and amassing stocks of the virus, gaining experience working with what experts believe is currently the most likely candidate to spark the next influenza pandemic. "That viral seed bank could be used if, as expected, the federal government approves a roughly $20-million proposal to have ID Biomedical make trial lots of H5N1 vaccine. "The more experience collectively as an industry we have with these types of strains, the better off the whole world is," Holler said." ctv.ca